Innovations For All: Swiss-Led Panel Looks At What Works, What Doesn’t 14/02/2018 William New The current innovation system has yielded many important innovations and extended human life, nobody disputes this. But what about the cases where it hasn’t and a problem persists? A panel of health experts organised recently by the Swiss government and including representatives of the pharmaceutical industry, the World Health Organization, academia, and a research institution held an unusually open and positive discussion that sought to get underneath the issue. Continue reading -> Do We Need A Global Body To Set Priorities For Diseases And Research? 14/02/2018 William New A recent panel of health experts gathered at the hallowed Swiss Intellectual Property Institute in Bern (which counts Albert Einstein among its alumni) tackled some of the toughest questions facing global health policymakers with an eye toward actually solving them and not just restating polarised positions. One of the ideas discussed at the event was how priorities for diseases and research are handled at the global level. Continue reading -> Trump Budget Would Slash Funding For Health, International Organisations 13/02/2018 William New The Trump administration this week proposed drastic cuts in funding for international activities including foreign policy and global health in 2019, while further building up military and big business activities. Programs related to international activities will have to prove their value to American interests and other countries are demanded to pay more, according to the proposed budget sent yesterday to Congress, which is ultimately expected to set about the task of restoring numerous programs. Continue reading -> Leaked Letter Shows Pressure On Colombia Not To Issue Compulsory Licence For Glivec 06/02/2018 William New A newly leaked 2016 letter from the CEO of Novartis to the president of Colombia, made available by Swiss group Public Eye, shows the level of concern the Swiss pharmaceutical company had over the effect of possible issuance of a compulsory licence for Novartis drug Glivec in the pivotal South American economy. Continue reading -> Medicines Innovation And Access: Swiss Stimulate New Thinking 06/02/2018 Catherine Saez BERN, Switzerland -- What if reaching the United Nations Sustainable Development Goals on access to health for all depended on the willingness of all actors to see beyond outdated dichotomies? The concept may seem obvious, but is easier described than done. In an effort to break silos, the Swiss Federal Institute of Intellectual Property (IPI) brought together stakeholders of all sides last week to discuss how to harness political and economic will to achieve innovation leading to new medicines that are available and affordable for all in need. Continue reading -> Biosimilar Industry Launches Information Campaign For Better Acceptance 05/02/2018 Catherine Saez The International Generic and Biosimilar medicines Association has launched an information campaign on biosimilar medicines in order to raise worldwide understanding and acceptance of biosimilar medicines. Continue reading -> FIND Announces Four New Collaborations To Address AMR 31/01/2018 Catherine Saez The Foundation for Innovative New Diagnostics (FIND) yesterday announced the release of a new strategy on antimicrobial resistance (AMR). Continue reading -> The Top 5 Issues In EU Medicines Policy For 2018 (Including IP) 30/01/2018 Guest contributor Yannis Natsis writes: There is a breakdown in communications between the pharmaceutical industry and Ministers of Health in Europe. The newly-deployed tactic of public, personalised attacks on national decision-makers who express concerns over high prices of medicines, reveal a change in the industry’s lobbying strategy that might damage the relationship irreparably. Continue reading -> Antimicrobial Benchmark For Industry Launched In Davos 23/01/2018 Catherine Saez Across the Alps from this week's World Health Organization Executive Board meeting, the first ever antimicrobial resistance benchmark was launched today at the World Economic Forum annual meeting in Davos. Continue reading -> Industry Alliance Report: Companies Invest In AMR R&D, Need More Pull Incentives 18/01/2018 Catherine Saez An alliance of over a hundred industries seeking to curb antimicrobial resistance launched its first report today. According to the report, a number of companies are heavily investing in research and development, and work to improve access to their diagnostic products and preventing therapies. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Do We Need A Global Body To Set Priorities For Diseases And Research? 14/02/2018 William New A recent panel of health experts gathered at the hallowed Swiss Intellectual Property Institute in Bern (which counts Albert Einstein among its alumni) tackled some of the toughest questions facing global health policymakers with an eye toward actually solving them and not just restating polarised positions. One of the ideas discussed at the event was how priorities for diseases and research are handled at the global level. Continue reading -> Trump Budget Would Slash Funding For Health, International Organisations 13/02/2018 William New The Trump administration this week proposed drastic cuts in funding for international activities including foreign policy and global health in 2019, while further building up military and big business activities. Programs related to international activities will have to prove their value to American interests and other countries are demanded to pay more, according to the proposed budget sent yesterday to Congress, which is ultimately expected to set about the task of restoring numerous programs. Continue reading -> Leaked Letter Shows Pressure On Colombia Not To Issue Compulsory Licence For Glivec 06/02/2018 William New A newly leaked 2016 letter from the CEO of Novartis to the president of Colombia, made available by Swiss group Public Eye, shows the level of concern the Swiss pharmaceutical company had over the effect of possible issuance of a compulsory licence for Novartis drug Glivec in the pivotal South American economy. Continue reading -> Medicines Innovation And Access: Swiss Stimulate New Thinking 06/02/2018 Catherine Saez BERN, Switzerland -- What if reaching the United Nations Sustainable Development Goals on access to health for all depended on the willingness of all actors to see beyond outdated dichotomies? The concept may seem obvious, but is easier described than done. In an effort to break silos, the Swiss Federal Institute of Intellectual Property (IPI) brought together stakeholders of all sides last week to discuss how to harness political and economic will to achieve innovation leading to new medicines that are available and affordable for all in need. Continue reading -> Biosimilar Industry Launches Information Campaign For Better Acceptance 05/02/2018 Catherine Saez The International Generic and Biosimilar medicines Association has launched an information campaign on biosimilar medicines in order to raise worldwide understanding and acceptance of biosimilar medicines. Continue reading -> FIND Announces Four New Collaborations To Address AMR 31/01/2018 Catherine Saez The Foundation for Innovative New Diagnostics (FIND) yesterday announced the release of a new strategy on antimicrobial resistance (AMR). Continue reading -> The Top 5 Issues In EU Medicines Policy For 2018 (Including IP) 30/01/2018 Guest contributor Yannis Natsis writes: There is a breakdown in communications between the pharmaceutical industry and Ministers of Health in Europe. The newly-deployed tactic of public, personalised attacks on national decision-makers who express concerns over high prices of medicines, reveal a change in the industry’s lobbying strategy that might damage the relationship irreparably. Continue reading -> Antimicrobial Benchmark For Industry Launched In Davos 23/01/2018 Catherine Saez Across the Alps from this week's World Health Organization Executive Board meeting, the first ever antimicrobial resistance benchmark was launched today at the World Economic Forum annual meeting in Davos. Continue reading -> Industry Alliance Report: Companies Invest In AMR R&D, Need More Pull Incentives 18/01/2018 Catherine Saez An alliance of over a hundred industries seeking to curb antimicrobial resistance launched its first report today. According to the report, a number of companies are heavily investing in research and development, and work to improve access to their diagnostic products and preventing therapies. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Trump Budget Would Slash Funding For Health, International Organisations 13/02/2018 William New The Trump administration this week proposed drastic cuts in funding for international activities including foreign policy and global health in 2019, while further building up military and big business activities. Programs related to international activities will have to prove their value to American interests and other countries are demanded to pay more, according to the proposed budget sent yesterday to Congress, which is ultimately expected to set about the task of restoring numerous programs. Continue reading -> Leaked Letter Shows Pressure On Colombia Not To Issue Compulsory Licence For Glivec 06/02/2018 William New A newly leaked 2016 letter from the CEO of Novartis to the president of Colombia, made available by Swiss group Public Eye, shows the level of concern the Swiss pharmaceutical company had over the effect of possible issuance of a compulsory licence for Novartis drug Glivec in the pivotal South American economy. Continue reading -> Medicines Innovation And Access: Swiss Stimulate New Thinking 06/02/2018 Catherine Saez BERN, Switzerland -- What if reaching the United Nations Sustainable Development Goals on access to health for all depended on the willingness of all actors to see beyond outdated dichotomies? The concept may seem obvious, but is easier described than done. In an effort to break silos, the Swiss Federal Institute of Intellectual Property (IPI) brought together stakeholders of all sides last week to discuss how to harness political and economic will to achieve innovation leading to new medicines that are available and affordable for all in need. Continue reading -> Biosimilar Industry Launches Information Campaign For Better Acceptance 05/02/2018 Catherine Saez The International Generic and Biosimilar medicines Association has launched an information campaign on biosimilar medicines in order to raise worldwide understanding and acceptance of biosimilar medicines. Continue reading -> FIND Announces Four New Collaborations To Address AMR 31/01/2018 Catherine Saez The Foundation for Innovative New Diagnostics (FIND) yesterday announced the release of a new strategy on antimicrobial resistance (AMR). Continue reading -> The Top 5 Issues In EU Medicines Policy For 2018 (Including IP) 30/01/2018 Guest contributor Yannis Natsis writes: There is a breakdown in communications between the pharmaceutical industry and Ministers of Health in Europe. The newly-deployed tactic of public, personalised attacks on national decision-makers who express concerns over high prices of medicines, reveal a change in the industry’s lobbying strategy that might damage the relationship irreparably. Continue reading -> Antimicrobial Benchmark For Industry Launched In Davos 23/01/2018 Catherine Saez Across the Alps from this week's World Health Organization Executive Board meeting, the first ever antimicrobial resistance benchmark was launched today at the World Economic Forum annual meeting in Davos. Continue reading -> Industry Alliance Report: Companies Invest In AMR R&D, Need More Pull Incentives 18/01/2018 Catherine Saez An alliance of over a hundred industries seeking to curb antimicrobial resistance launched its first report today. According to the report, a number of companies are heavily investing in research and development, and work to improve access to their diagnostic products and preventing therapies. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Leaked Letter Shows Pressure On Colombia Not To Issue Compulsory Licence For Glivec 06/02/2018 William New A newly leaked 2016 letter from the CEO of Novartis to the president of Colombia, made available by Swiss group Public Eye, shows the level of concern the Swiss pharmaceutical company had over the effect of possible issuance of a compulsory licence for Novartis drug Glivec in the pivotal South American economy. Continue reading -> Medicines Innovation And Access: Swiss Stimulate New Thinking 06/02/2018 Catherine Saez BERN, Switzerland -- What if reaching the United Nations Sustainable Development Goals on access to health for all depended on the willingness of all actors to see beyond outdated dichotomies? The concept may seem obvious, but is easier described than done. In an effort to break silos, the Swiss Federal Institute of Intellectual Property (IPI) brought together stakeholders of all sides last week to discuss how to harness political and economic will to achieve innovation leading to new medicines that are available and affordable for all in need. Continue reading -> Biosimilar Industry Launches Information Campaign For Better Acceptance 05/02/2018 Catherine Saez The International Generic and Biosimilar medicines Association has launched an information campaign on biosimilar medicines in order to raise worldwide understanding and acceptance of biosimilar medicines. Continue reading -> FIND Announces Four New Collaborations To Address AMR 31/01/2018 Catherine Saez The Foundation for Innovative New Diagnostics (FIND) yesterday announced the release of a new strategy on antimicrobial resistance (AMR). Continue reading -> The Top 5 Issues In EU Medicines Policy For 2018 (Including IP) 30/01/2018 Guest contributor Yannis Natsis writes: There is a breakdown in communications between the pharmaceutical industry and Ministers of Health in Europe. The newly-deployed tactic of public, personalised attacks on national decision-makers who express concerns over high prices of medicines, reveal a change in the industry’s lobbying strategy that might damage the relationship irreparably. Continue reading -> Antimicrobial Benchmark For Industry Launched In Davos 23/01/2018 Catherine Saez Across the Alps from this week's World Health Organization Executive Board meeting, the first ever antimicrobial resistance benchmark was launched today at the World Economic Forum annual meeting in Davos. Continue reading -> Industry Alliance Report: Companies Invest In AMR R&D, Need More Pull Incentives 18/01/2018 Catherine Saez An alliance of over a hundred industries seeking to curb antimicrobial resistance launched its first report today. According to the report, a number of companies are heavily investing in research and development, and work to improve access to their diagnostic products and preventing therapies. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Medicines Innovation And Access: Swiss Stimulate New Thinking 06/02/2018 Catherine Saez BERN, Switzerland -- What if reaching the United Nations Sustainable Development Goals on access to health for all depended on the willingness of all actors to see beyond outdated dichotomies? The concept may seem obvious, but is easier described than done. In an effort to break silos, the Swiss Federal Institute of Intellectual Property (IPI) brought together stakeholders of all sides last week to discuss how to harness political and economic will to achieve innovation leading to new medicines that are available and affordable for all in need. Continue reading -> Biosimilar Industry Launches Information Campaign For Better Acceptance 05/02/2018 Catherine Saez The International Generic and Biosimilar medicines Association has launched an information campaign on biosimilar medicines in order to raise worldwide understanding and acceptance of biosimilar medicines. Continue reading -> FIND Announces Four New Collaborations To Address AMR 31/01/2018 Catherine Saez The Foundation for Innovative New Diagnostics (FIND) yesterday announced the release of a new strategy on antimicrobial resistance (AMR). Continue reading -> The Top 5 Issues In EU Medicines Policy For 2018 (Including IP) 30/01/2018 Guest contributor Yannis Natsis writes: There is a breakdown in communications between the pharmaceutical industry and Ministers of Health in Europe. The newly-deployed tactic of public, personalised attacks on national decision-makers who express concerns over high prices of medicines, reveal a change in the industry’s lobbying strategy that might damage the relationship irreparably. Continue reading -> Antimicrobial Benchmark For Industry Launched In Davos 23/01/2018 Catherine Saez Across the Alps from this week's World Health Organization Executive Board meeting, the first ever antimicrobial resistance benchmark was launched today at the World Economic Forum annual meeting in Davos. Continue reading -> Industry Alliance Report: Companies Invest In AMR R&D, Need More Pull Incentives 18/01/2018 Catherine Saez An alliance of over a hundred industries seeking to curb antimicrobial resistance launched its first report today. According to the report, a number of companies are heavily investing in research and development, and work to improve access to their diagnostic products and preventing therapies. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Biosimilar Industry Launches Information Campaign For Better Acceptance 05/02/2018 Catherine Saez The International Generic and Biosimilar medicines Association has launched an information campaign on biosimilar medicines in order to raise worldwide understanding and acceptance of biosimilar medicines. Continue reading -> FIND Announces Four New Collaborations To Address AMR 31/01/2018 Catherine Saez The Foundation for Innovative New Diagnostics (FIND) yesterday announced the release of a new strategy on antimicrobial resistance (AMR). Continue reading -> The Top 5 Issues In EU Medicines Policy For 2018 (Including IP) 30/01/2018 Guest contributor Yannis Natsis writes: There is a breakdown in communications between the pharmaceutical industry and Ministers of Health in Europe. The newly-deployed tactic of public, personalised attacks on national decision-makers who express concerns over high prices of medicines, reveal a change in the industry’s lobbying strategy that might damage the relationship irreparably. Continue reading -> Antimicrobial Benchmark For Industry Launched In Davos 23/01/2018 Catherine Saez Across the Alps from this week's World Health Organization Executive Board meeting, the first ever antimicrobial resistance benchmark was launched today at the World Economic Forum annual meeting in Davos. Continue reading -> Industry Alliance Report: Companies Invest In AMR R&D, Need More Pull Incentives 18/01/2018 Catherine Saez An alliance of over a hundred industries seeking to curb antimicrobial resistance launched its first report today. According to the report, a number of companies are heavily investing in research and development, and work to improve access to their diagnostic products and preventing therapies. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
FIND Announces Four New Collaborations To Address AMR 31/01/2018 Catherine Saez The Foundation for Innovative New Diagnostics (FIND) yesterday announced the release of a new strategy on antimicrobial resistance (AMR). Continue reading -> The Top 5 Issues In EU Medicines Policy For 2018 (Including IP) 30/01/2018 Guest contributor Yannis Natsis writes: There is a breakdown in communications between the pharmaceutical industry and Ministers of Health in Europe. The newly-deployed tactic of public, personalised attacks on national decision-makers who express concerns over high prices of medicines, reveal a change in the industry’s lobbying strategy that might damage the relationship irreparably. Continue reading -> Antimicrobial Benchmark For Industry Launched In Davos 23/01/2018 Catherine Saez Across the Alps from this week's World Health Organization Executive Board meeting, the first ever antimicrobial resistance benchmark was launched today at the World Economic Forum annual meeting in Davos. Continue reading -> Industry Alliance Report: Companies Invest In AMR R&D, Need More Pull Incentives 18/01/2018 Catherine Saez An alliance of over a hundred industries seeking to curb antimicrobial resistance launched its first report today. According to the report, a number of companies are heavily investing in research and development, and work to improve access to their diagnostic products and preventing therapies. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
The Top 5 Issues In EU Medicines Policy For 2018 (Including IP) 30/01/2018 Guest contributor Yannis Natsis writes: There is a breakdown in communications between the pharmaceutical industry and Ministers of Health in Europe. The newly-deployed tactic of public, personalised attacks on national decision-makers who express concerns over high prices of medicines, reveal a change in the industry’s lobbying strategy that might damage the relationship irreparably. Continue reading -> Antimicrobial Benchmark For Industry Launched In Davos 23/01/2018 Catherine Saez Across the Alps from this week's World Health Organization Executive Board meeting, the first ever antimicrobial resistance benchmark was launched today at the World Economic Forum annual meeting in Davos. Continue reading -> Industry Alliance Report: Companies Invest In AMR R&D, Need More Pull Incentives 18/01/2018 Catherine Saez An alliance of over a hundred industries seeking to curb antimicrobial resistance launched its first report today. According to the report, a number of companies are heavily investing in research and development, and work to improve access to their diagnostic products and preventing therapies. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Antimicrobial Benchmark For Industry Launched In Davos 23/01/2018 Catherine Saez Across the Alps from this week's World Health Organization Executive Board meeting, the first ever antimicrobial resistance benchmark was launched today at the World Economic Forum annual meeting in Davos. Continue reading -> Industry Alliance Report: Companies Invest In AMR R&D, Need More Pull Incentives 18/01/2018 Catherine Saez An alliance of over a hundred industries seeking to curb antimicrobial resistance launched its first report today. According to the report, a number of companies are heavily investing in research and development, and work to improve access to their diagnostic products and preventing therapies. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Industry Alliance Report: Companies Invest In AMR R&D, Need More Pull Incentives 18/01/2018 Catherine Saez An alliance of over a hundred industries seeking to curb antimicrobial resistance launched its first report today. According to the report, a number of companies are heavily investing in research and development, and work to improve access to their diagnostic products and preventing therapies. Continue reading -> Posts navigation Older postsNewer posts